medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-19-38-43medalphabet-2790Research ArticleСтатьиТромбозы на фоне COVID-19 у лиц среднего возрастаThrombosis on background of COVID-19 in middle-aged peoplehttps://orcid.org/0000-0002-1250-8798ХидироваЛ. Д.KhidirovaL. D.

Людмила Даудовна Хидирова, д. м. н., проф.

ФГБОУ ВО «Новосибирский государственный медицинский университет»

кафедра фармакологии, клинической фармакологии и доказательной медицины

Новосибирск

Lyudmila D. Hidirova, DM Sci (habil.), professor

Dept of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine

Novosibirsk

h_ludmila73@mail.ruhttps://orcid.org/0000-0002-4735-3861ИльиныхН. П.IlyinykhN. P.

Наталья Павловна Ильиных, студентка

VI курс

ФГБОУ ВО «Новосибирский государственный медицинский университет»

Новосибирск

Natalia P. Ilinykh, 6th-year student

Novosibirsk

nataliy1998stu@yandex.ruhttps://orcid.org/0000-0002-1093-8938МадоновП. Г.MadonovP. G.

Павел Геннадьевич Мадонов, д. м. н., проф., зав. кафедрой

ФГБОУ ВО «Новосибирский государственный медицинский университет»

кафедра фармакологии, клинической фармакологии и доказательной медицины

Новосибирск

Pavel G. Madonov, DM Sci (habil.), professor, head of Dept

Dept of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine

Novosibirsk

madonov@scpb.ruМинздрав РоссииРоссияNovosibirsk State Medical UniversityRussian Federation202216102022019Современная лаборатория (2)3843Copyright © Хидирова Л.Д., Ильиных Н.П., Мадонов П.Г., 20222022Хидирова Л.Д., Ильиных Н.П., Мадонов П.Г.Khidirova L.D., Ilyinykh N.P., Madonov P.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2790

   В данном обзоре представлены особенности коагулопатии и тромботического риска при COVID-19 у лиц среднего возраста. Показано последовательное увеличение D-димера и наличие тромбоза и ТЭЛА у тяжелобольных пациентов среднего возраста с COVID-19 при снижении других параметров свертывания крови, таких как фибриноген, тромбоциты или антитромбин, которые связаны с ДВС-синдромом. Следовательно, есть потребность в выявлении и предотвращении повышенного риска тромботических событий на ранней стадии повреждения органов, насколько это возможно. Также рассматривается применение тромболитической терапии. В настоящее время прилагаются большие усилия международных медицинских и научных сообществ, новая короновирусная инфекция COVID-19 является глобальной проблемой и прогноз для госпитализированных пациентов с COVID-19, особенно при критической форме, продолжает оставаться неблагоприятным не только для пожилых и старых пациентов, но и для лиц среднего возраста. Несмотря на то что это заболевание считается многофакторным, тромботические осложнения играют важную роль в дальнейшем прогнозе у этой категории пациентов.

   This review presents the features of coagulopathy and thrombotic risk in COVID-19 in middle-aged people. A consistent increase in the D-dimer and the presence of thrombosis and PE in seriously ill middle-aged patients with COVID-19 was shown with a decrease in other blood clotting parameters, such as fibrinogen, platelets or antithrombin, which are associated with DIC syndrome. Therefore, there is a need to identify an increased risk of thrombotic events at an early stage and prevent thrombotic events and organ damage as much as possible. The use of thrombolytic therapy is also being considered. Currently, great efforts are being made by the international medical and scientific communities, the new coronovirus infection COVID-19 is a problem and the prognosis for hospitalized patients with COVID-19, especially in the critical form, continues to be unfavorable not only for elderly and old patients, but also for middle-aged patients. age. Despite the fact that this disease is considered multifactorial, thrombotic complications play an important role in the further prognosis in this category of patients.

COVID-19D-димерSARS-CoVтромботический рискARDSACE 2COVID-19D-dimerSARS-CoVthrombotic riskARDSACE 2ReferencesZhang L., Yan X., Fan Q., Liu H., Liu X., Liu Z., Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020; 18: 1324–1329. https://doi.org/10.1111/jth.14859Zhang L., Yan X., Fan Q., Liu H., Liu X., Liu Z., Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020; 18: 1324–1329. https://doi.org/10.1111/jth.14859Klok F. A., Kruip M. J., van der Meer N. J., Arbous M. S., Gommers D. A., Kant K. M., Kaptein F. H., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020, 191: 145–147. https://doi.org/10.1016/j.thromres.2020.04.013Klok F. A., Kruip M. J., van der Meer N. J., Arbous M. S., Gommers D. A., Kant K. M., Kaptein F. H., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020, 191: 145–147. https://doi.org/10.1016/j.thromres.2020.04.013Adam S. S., Key N. S., Greenberg C. S. D-dimer antigen: current concepts and future prospects. Blood 2009, 113: 2878–2887 https://doi.org/10.1182/blood-2008–06–165845Adam S. S., Key N. S., Greenberg C. S. D-dimer antigen: current concepts and future prospects. Blood 2009, 113: 2878–2887 https://doi.org/10.1182/blood-2008–06–165845Li Y., Zhao K., Wei H., Chen W., Wang W., Jia L., Liu Q., et al. Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol 2020. https://doi.org/10.1111/bjh.16811Li Y., Zhao K., Wei H., Chen W., Wang W., Jia L., Liu Q., et al. Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol 2020. https://doi.org/10.1111/bjh.16811Wang T., Chen R., Liu C., Liang W., Guan W., Tang R., Tang C., et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haemato 2020; (7): 362–363. https://doi.org/10.1016/s2352–3026(20)30109–5Wang T., Chen R., Liu C., Liang W., Guan W., Tang R., Tang C., et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haemato 2020; (7): 362–363. https://doi.org/10.1016/s2352–3026(20)30109–5Ñamendys-Silva S. A. Respiratory support for patients with COVID-19 infection. Lancet Respir Med 2020, 8: 18. https://doi.org/10.1016/S2213–2600(20)30110–7Ñamendys-Silva S. A. Respiratory support for patients with COVID-19 infection. Lancet Respir Med 2020, 8: 18. https://doi.org/10.1016/S2213–2600(20)30110–7De Wit E., van Doremalen N., Falzarano D., Munster V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14 (8): 523–534. https://doi.org/10.1038/nrmicro.2016.81De Wit E., van Doremalen N., Falzarano D., Munster V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14 (8): 523–534. https://doi.org/10.1038/nrmicro.2016.81Zhang H., Penninger J. M., Li Y., Zhong N., Slutsky A. S. Angiotensin-converting enzyme 2 (ACE 2) as a SARS-CoV-2 receptor: molecular me chanisms and potential therapeutic target. Intensive Care Med. 2020; 46 (4): 586–590. https://doi.org/10.1007/s00134–020–05985–9Zhang H., Penninger J. M., Li Y., Zhong N., Slutsky A. S. Angiotensin-converting enzyme 2 (ACE 2) as a SARS-CoV-2 receptor: molecular me chanisms and potential therapeutic target. Intensive Care Med. 2020; 46 (4): 586–590. https://doi.org/10.1007/s00134–020–05985–9Ng K., Wu A., Cheng V., et al. Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome. Postgrad Med J. 2005; 81 (956): 3. https://doi.org/10.1136/pgmj.2004.030049Ng K., Wu A., Cheng V., et al. Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome. Postgrad Med J. 2005; 81 (956): 3. https://doi.org/10.1136/pgmj.2004.030049Dosquet C., Weill D., Wautier J. L. Cytokines and thrombosis. J Cardiovasc Pharmacol. 1995; 25 (suppl 2): S 13–S 19. https://doi.org/10.1097/00005344–199500252–00004Dosquet C., Weill D., Wautier J. L. Cytokines and thrombosis. J Cardiovasc Pharmacol. 1995; 25 (suppl 2): S 13–S 19. https://doi.org/10.1097/00005344–199500252–00004Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (4): 844–847. https:// doi: 10.1111/jth.14768Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (4): 844–847. https:// doi: 10.1111/jth.14768Xu J. F., Wang L., Zhao L., et al. Risk assessment of venous thromboembolism and bleeding in COVID-19 patients. Research Sqare. 2020. https://doi.org/10.21203/rs.3.rs-18340/v1Xu J. F., Wang L., Zhao L., et al. Risk assessment of venous thromboembolism and bleeding in COVID-19 patients. Research Sqare. 2020. https://doi.org/10.21203/rs.3.rs-18340/v1Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (6): 1421–1424.Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (6): 1421–1424.Klok F. A., Kruip M. J., Van der Meer N. J., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. https://doi.org/10.1016/j.thromres.2020.04.013Klok F. A., Kruip M. J., Van der Meer N. J., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. https://doi.org/10.1016/j.thromres.2020.04.013Demelo-Rodriguez P., Cervilla-Munoz E., Ordieres-Ortega L., et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020; 192: 23–26. https://doi.org/10.1016/j.thromres.2020.05.018Demelo-Rodriguez P., Cervilla-Munoz E., Ordieres-Ortega L., et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020; 192: 23–26. https://doi.org/10.1016/j.thromres.2020.05.018Eljilany I., Elzouki A. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Sus-pected Venous Thromboembolism: A Narrative Review. Vasc Health Risk Manag. 2020 Nov 13; 16: 455–462. https://doi.org/10.2147/VHRM.S280962Eljilany I., Elzouki A. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Sus-pected Venous Thromboembolism: A Narrative Review. Vasc Health Risk Manag. 2020 Nov 13; 16: 455–462. https://doi.org/10.2147/VHRM.S280962Zhang Y., Xiao M., Zhang S., et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020; 382 (17): e38. https://doi.org/10.1056/nejmc2007575Zhang Y., Xiao M., Zhang S., et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020; 382 (17): e38. https://doi.org/10.1056/nejmc2007575Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18 (5): 1094–1099. https://doi.org/10.1111/jth.14817Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18 (5): 1094–1099. https://doi.org/10.1111/jth.14817Liu Y., Mu S., Li X., Liang Y., Wang L., Ma X. Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions. J Surg Res. 2019; 6 (238): 175–185. https://doi.org/10.1016/j.jss.2019.01.020Liu Y., Mu S., Li X., Liang Y., Wang L., Ma X. Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions. J Surg Res. 2019; 6 (238): 175–185. https://doi.org/10.1016/j.jss.2019.01.020Bikdeli B., Madhavan M. V., Jimenez D., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020; 75 (23): 2950–2973. https://doi.org/10.1016/j.jacc.2020.04.031Bikdeli B., Madhavan M. V., Jimenez D., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020; 75 (23): 2950–2973. https://doi.org/10.1016/j.jacc.2020.04.031Wang J., Hajizadeh N., Moore E. E., et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14828.Wang J., Hajizadeh N., Moore E. E., et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14828.Thachil J., Tang N., Gando S., Falanga A., Cattaneo M., Levi M. et al. ISTH interim guidance onrecognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis. 2020; 3: 14810. [Epub ahead of print]. https://doi.org/10.1016/j.jacc.2020.04.031Thachil J., Tang N., Gando S., Falanga A., Cattaneo M., Levi M. et al. ISTH interim guidance onrecognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis. 2020; 3: 14810. [Epub ahead of print]. https://doi.org/10.1016/j.jacc.2020.04.031Bhatraju P. K., Ghassemieh B. J., Nichols M., et al. Covid-19 in critically ill patients in the Seattle region – case series. N Engl J Med 2020; 382: 2012–2022. https://doi.org/10.1056/nejmoa2004500Bhatraju P. K., Ghassemieh B. J., Nichols M., et al. Covid-19 in critically ill patients in the Seattle region – case series. N Engl J Med 2020; 382: 2012–2022. https://doi.org/10.1056/nejmoa2004500Yang X., Yu Y., Xu J., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8 (05): 475–481. https://doi.org/10.1016/s2213–2600(20)30079–5Yang X., Yu Y., Xu J., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8 (05): 475–481. https://doi.org/10.1016/s2213–2600(20)30079–5Klypa T. V., Bychinina M. V., Mandel I. A., Andreichenko S. A., Minets A. I., Kolyshkina N. A., Troitsky A. V., Clinical characteristics of patients with COVID-19 admitted to the intensive care unit. Predictors of severe flow Volume. 2020; 11 (2): 200–220. https://doi.org/10.17816/clinpract34182Klypa T. V., Bychinina M. V., Mandel I. A., Andreichenko S. A., Minets A. I., Kolyshkina N. A., Troitsky A. V., Clinical characteristics of patients with COVID-19 admitted to the intensive care unit. Predictors of severe flow Volume. 2020; 11 (2): 200–220. https://doi.org/10.17816/clinpract34182Published online April 15, 2020. Panigada M., Bottino N., Tagliabue P., et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. Published online April 17, 2020 https://doi.org/10.1111/jth.14850Published online April 15, 2020. Panigada M., Bottino N., Tagliabue P., et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. Published online April 17, 2020 https://doi.org/10.1111/jth.14850Panigada M., Bottino N., Tagliabue P., et al. Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J ThrombHaemost. 2020; 18 (7): 1738–42. Yakhontov D. A. https://doi.org/10.1111/jth.14850.Panigada M., Bottino N., Tagliabue P., et al. Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J ThrombHaemost. 2020; 18 (7): 1738–42. Yakhontov D. A. https://doi.org/10.1111/jth.14850.Mahmoud B. Malas et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. Lancet 1 Dec 2020 https://doi.org/10.1016/j.eclinm.2020.100639Mahmoud B. Malas et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. Lancet 1 Dec 2020 https://doi.org/10.1016/j.eclinm.2020.100639Behnood Bikdeli, Mahesh V. Madhavan, Aakriti Gupta et al.Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromboembolism. 2020; 18 (7): 1738–1742. https://doi.org/10.1055/s-0040-1713152Behnood Bikdeli, Mahesh V. Madhavan, Aakriti Gupta et al.Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromboembolism. 2020; 18 (7): 1738–1742. https://doi.org/10.1055/s-0040-1713152Thromb Haemost, 2020 Georg Thieme Verlag KG Stuttgart · New York. Li H., Liu L., Zhang D., et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020; 395 (10235): 1517–1520 https://doi.org/10.1016/s0140–6736(20)30920-x.Thromb Haemost, 2020 Georg Thieme Verlag KG Stuttgart · New York. Li H., Liu L., Zhang D., et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020; 395 (10235): 1517–1520 https://doi.org/10.1016/s0140–6736(20)30920-x.Pulmonary and cardiac pathology in African American patients with COVID-19: An autopsy series from New Orleans. S. Fox, A. Akmatbekov, J. Harbert [et al.]. Text (visual): unmediated Lancet Respir Med. 2020; 8: 681–686 https://doi.org/10.1016/s2213–2600(20)30243–5Pulmonary and cardiac pathology in African American patients with COVID-19: An autopsy series from New Orleans. S. Fox, A. Akmatbekov, J. Harbert [et al.]. Text (visual): unmediated Lancet Respir Med. 2020; 8: 681–686 https://doi.org/10.1016/s2213–2600(20)30243–5Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. C. Wu, X. Chen, Y. Cai [et al.]. Text (visual): unmediated JAMA Intern. Med. 2020; 4 (8): 934 https://doi.org/10.1001/jamainternmed.2020.0994Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. C. Wu, X. Chen, Y. Cai [et al.]. Text (visual): unmediated JAMA Intern. Med. 2020; 4 (8): 934 https://doi.org/10.1001/jamainternmed.2020.0994SARS, MERS, and novel coronavirus (COVID-19) epidemics, the newest and big-gest global health threats: whatlessons have we learned? N. Peeri, N. Shrestha, M. S. Rahman [et al.]. Text (visual: unmediated Int JEpidemiol. 2020; 49: 717–726 https://doi.org/10.1093/ije/dyaa033SARS, MERS, and novel coronavirus (COVID-19) epidemics, the newest and big-gest global health threats: whatlessons have we learned? N. Peeri, N. Shrestha, M. S. Rahman [et al.]. Text (visual: unmediated Int JEpidemiol. 2020; 49: 717–726 https://doi.org/10.1093/ije/dyaa033The epidemiology, diagnosis, and treatment of COVID-19. P. Zhai, Y. Ding, X. Wu, J. Long [et al.]. Text (visual): unmediated Int J Antimicrob Agents. 2020; 55 (5): 105–115 https://doi.org/10.1016/j.ijantimicag.2020.105955The epidemiology, diagnosis, and treatment of COVID-19. P. Zhai, Y. Ding, X. Wu, J. Long [et al.]. Text (visual): unmediated Int J Antimicrob Agents. 2020; 55 (5): 105–115 https://doi.org/10.1016/j.ijantimicag.2020.105955Swystun L. The role of leukocytes in thrombosis. L. Swystun, P. Liaw. Text (visual): unmediated Blood. 2016; 128: 753–762 https://doi.org/10.1182/blood-2016–05–718114Swystun L. The role of leukocytes in thrombosis. L. Swystun, P. Liaw. Text (visual): unmediated Blood. 2016; 128: 753–762 https://doi.org/10.1182/blood-2016–05–718114Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital inMilan, Italy. C. Lodigiani, G. Iapichino, L. Carenzo [et al.]. Text (visual): unmediated Thromb Res. 2020; 191: 9–14 https://doi.org/10.1016/j.thromres.2020.04.024Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital inMilan, Italy. C. Lodigiani, G. Iapichino, L. Carenzo [et al.]. Text (visual): unmediated Thromb Res. 2020; 191: 9–14 https://doi.org/10.1016/j.thromres.2020.04.024Inciardi R. M., Adamo M., Lupi L., et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020; 41 (19): 1821–9. https://doi.org/10.1093/eurheartj/ehaa388.Inciardi R. M., Adamo M., Lupi L., et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020; 41 (19): 1821–9. https://doi.org/10.1093/eurheartj/ehaa388.Terpos E., Ntanasis-Stathopoulos I., Elalamy I., et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95 (7): 834–47. https://doi.org/10.1002/ajh.25829Terpos E., Ntanasis-Stathopoulos I., Elalamy I., et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95 (7): 834–47. https://doi.org/10.1002/ajh.25829Miftode R. S., Petris A. O., Onofrei A. V., et al. The Novel Perspectives Opened by ST2 in the Pandemic: A Review of Its Role in the Diagnosis and Prognosis of Patients with Heart Failure and COVID-19. Diagnostics (Basel). 2021; 11 (2): 175. https://doi.org/10.3390/diagnostics11020175Miftode R. S., Petris A. O., Onofrei A. V., et al. The Novel Perspectives Opened by ST2 in the Pandemic: A Review of Its Role in the Diagnosis and Prognosis of Patients with Heart Failure and COVID-19. Diagnostics (Basel). 2021; 11 (2): 175. https://doi.org/10.3390/diagnostics11020175Gumerov R. M., Gareeva D. F., Davtyan P. A., Rakhimova R. F., Musin T. I., Zagidullin S. Z., Pushkareva A. E., Plotnikova M. R., Ishmetov V. S., Pavlov V. N., Motloch L. J., Zagidullin N. S. Serum biomarkers of cardiovascular complications in COVID-19. Russian Journal of Cardiology. 2021; 26 (2S): 4456. (In Russ.) https://doi.org/10.15829/1560–4071–2021–4456Gumerov R. M., Gareeva D. F., Davtyan P. A., Rakhimova R. F., Musin T. I., Zagidullin S. Z., Pushkareva A. E., Plotnikova M. R., Ishmetov V. S., Pavlov V. N., Motloch L. J., Zagidullin N. S. Serum biomarkers of cardiovascular complications in COVID-19. Russian Journal of Cardiology. 2021; 26 (2S): 4456. (In Russ.) https://doi.org/10.15829/1560–4071–2021–4456Khidirova L. D., Fedoruk V. A., Vasiliev K. O. The role of a new coronavirus infection caused by the SARS-CoV-2 virusin the manifestation of multisystem inflammatory syndrome. Preventive medicine. 2021; 24 (6): 110–115. https://doi.org/10.17116/profmed202124061110Khidirova L. D., Fedoruk V. A., Vasiliev K. O. The role of a new coronavirus infection caused by the SARS-CoV-2 virusin the manifestation of multisystem inflammatory syndrome. Preventive medicine. 2021; 24 (6): 110–115. https://doi.org/10.17116/profmed202124061110Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017; 39 (5): 529–539. DOI: 10.1007/s00281–017–0629-x.Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017; 39 (5): 529–539. DOI: 10.1007/s00281–017–0629-x.Schrezenmeier E., Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020; 16 (3): 155–166. DOI: 10.1038/s41584–020–0372-x.Schrezenmeier E., Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020; 16 (3): 155–166. DOI: 10.1038/s41584–020–0372-x.Maurice J. S., Lalonde T., Shitsin H. & Liu U. R. Lessons from the Past: possible options for urgent prevention and treatment of severe acute respiratory infections caused by 2019-nCoV. Chemical biochem. (2020) https://doi.org/10.1002/cbic.202000047Maurice J. S., Lalonde T., Shitsin H. & Liu U. R. Lessons from the Past: possible options for urgent prevention and treatment of severe acute respiratory infections caused by 2019-nCoV. Chemical biochem. (2020) https://doi.org/10.1002/cbic.202000047Evidence-based medicine in questions and answers: monograph. D. A. Yakhontov. Novosibirsk: LLC ‘Printing House’, 2012; 326.Evidence-based medicine in questions and answers: monograph. D. A. Yakhontov. Novosibirsk: LLC ‘Printing House’, 2012; 326.Schein J. R., White C. M., Nelson W. W., Kluger J., Mearns E. S., Coleman C. I. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J 2016; 14: 14. https://doi.org/10.1186/s12959–016–0088-ySchein J. R., White C. M., Nelson W. W., Kluger J., Mearns E. S., Coleman C. I. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J 2016; 14: 14. https://doi.org/10.1186/s12959–016–0088-yBikdeli B., Madhavan M. V., Jimenez D., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020. https://doi.org/10.1016/j.jacc.2020.04.031Bikdeli B., Madhavan M. V., Jimenez D., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020. https://doi.org/10.1016/j.jacc.2020.04.031Agrawal U., Raju R., Udvadia Z. F. Favipiravir: A new and emerging antiviral variant in COVID-19. Med. J. Indian Armed Forces 2020; 76: 370–376. https://doi.org/10.1016/j.mjafi.2020.08.004Agrawal U., Raju R., Udvadia Z. F. Favipiravir: A new and emerging antiviral variant in COVID-19. Med. J. Indian Armed Forces 2020; 76: 370–376. https://doi.org/10.1016/j.mjafi.2020.08.004Z. Varga, A. J Flammer, P. Steiger et al. Offline: COVID-19-bewilderment and frankness. The Lancet. 2020; 3951178 https://doi.org/10.1016/S0140–6736(20)30937–5Z. Varga, A. J Flammer, P. Steiger et al. Offline: COVID-19-bewilderment and frankness. The Lancet. 2020; 3951178 https://doi.org/10.1016/S0140–6736(20)30937–5Madonov P. G., Khidirova L. D., Derisheva D. A. Neuropsychiatric features of current COVID-19 pandemic (analysis of foreign publications in 2020). Medical Alphabet. 2020; (33): 58–61. (In Russ.) https://doi.org/10.33667/2078–5631–2020–33–58–61Madonov P. G., Khidirova L. D., Derisheva D. A. Neuropsychiatric features of current COVID-19 pandemic (analysis of foreign publications in 2020). Medical Alphabet. 2020; (33): 58–61. (In Russ.) https://doi.org/10.33667/2078–5631–2020–33–58–61

The authors declare that there are no conflicts of interest present.